Abstract
Background. A 63-year-old man with an unresectable multifocal hepatocellular carcinoma (HCC) presented with upper abdominal discomfort, nausea and vomiting. We report a case of variant angina in a patient affected by unresectable HCC under chronic treatment with sorafenib. Spontaneous spasm occurred during cardiac catheterization and was revealed during coronary angiogram with the unusual feature of a retrograde transient filling of a contralateral branch.
Investigations. Electrocardiogram, cardiac catheterization, chest X-ray, emergency ECG.
Diagnosis. Variant angina induced by sorafenib treatment mimicking infero-posterior ST-elevation myocardial infarction (STEMI).
Management. High-dose calcium-antagonists and nitrates were initially given intravenously and then orally. Sorafenib therapy was then resumed without further symptoms. Restaging of the cancer revealed unexpected local recurrence and the patient died 1 month after receiving palliative care. We contend that the effects of sorafenib treatment were primarily responsible for the major cardiovascular event observed in this case, and it is important for clinicians to be aware of this possible severe complication of sorafenib therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Prinzmetal, M., Kennamer, R., Merliss, R., Wada, T. & Bor, N. Angina pectoris. I. A variant form of angina pectoris; preliminary report. Am. J. Med. 27, 375–388 (1959).
Lanza, G. A. et al. Current clinical features, diagnostic assessment and prognostic determinants of patients with variant angina. Int. J. Cardiol. 118, 41–47 (2007).
Stern, S. & Bayes de Luna, A. Coronary artery spasm: a 2009 update. Circulation 119, 2531–2534 (2009).
Luwaert, R. J., Descamps, O., Majois, F., Chaudron, J. M. & Beauduin, M. Coronary artery spasm induced by 5-fluorouracil. Eur. Heart J. 12, 468–470 (1991).
Yoo, S. Y. & Kim, J. Y. Recent insights into the mechanisms of vasospastic angina. Korean Circ. J. 39, 505–511 (2009).
Shepherd, J. T. & Katusic, Z. S. Endothelium-derived vasoactive factors: I. Endothelium-dependent relaxation. Hypertension 18 (Suppl. 5), 76–85 (1991).
Kugiyama, K. et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 94, 266–271 (1996).
Moncada, S., Palmer, R. M. & Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109–142 (1991).
Kandabashi, T. et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation 101, 1319–1323 (2000).
Miwa, K., Fujita, M. & Sasayama, S. Recent insights into the mechanisms, predisposing factors, and racial differences of coronary vasospasm. Heart Vessels 20, 1–7 (2005).
Murad, F. Nitric oxide and cyclic GMP in cell signaling and drug development. N. Engl. J. Med. 355, 2003–2011 (2006).
Norman, P. Kinase therapeutic pipelines: an assessment of targets and agents in development. Insight Pharma. Reports (2007).
Ivy, S. P., Wick, J. Y. & Kaufman, B. M. An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 6, 569–579 (2009).
Chen, M. H., Kerkelä, R. & Force, T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118, 84–95 (2008).
Force, T., Krause, D. S. & Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332–344 (2007).
Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099–7109 (2004).
Khakoo, A. Y. & Yeh, E. T. Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat. Clin. Pract. Oncol. 5, 655–667 (2008).
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
Schmidinger, M. et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26, 5204–5212 (2008).
de Boer, R. A., Siebelink, H. J., Tio, R. A., Boomsma, F. & van Veldhuisen, D. J. Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur. J. Heart Fail. 3, 331–333 (2001).
Arima, Y. et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J. Cardiol. 54, 512–515 (2009).
Shepherd, R. M. et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood 108, 3662–3667 (2006).
Chu, T. F. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011–2019 (2007).
Pawlak, G. & Helfman, D. M. Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts. Mol. Biol. Cell 13, 336–347 (2002).
Hennenberg, M. et al. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br. J. Pharmacol. 157, 258–270 (2009).
Mavria, G. et al. ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 9, 33–44 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Porto, I., Leo, A., Miele, L. et al. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 7, 476–480 (2010). https://doi.org/10.1038/nrclinonc.2010.67
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.67
This article is cited by
-
Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
Current Oncology Reports (2016)
-
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
BMC Cancer (2012)
-
Sorafenib-associated multivessel coronary artery vasospasm
Herz (2011)